Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)
China · Delayed Price · Currency is CNY 44.65
-1.88 (-4.04%)
Sep 11, 2026, 3:00 PM CST
SHA:688513 Revenue
Chengdu Easton Biopharmaceuticals had revenue of 332.64M CNY in the quarter ending June 30, 2026, a decrease of -4.64%. This brings the company's revenue in the last twelve months to 1.34B, up 0.09% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%.
Revenue (ttm)
1.34B
Revenue Growth
+0.09%
P/S Ratio
6.05
Revenue / Employee
943.39K
Employees
1,480
Market Cap
8.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.33B | -18.37M | -1.36% |
| Dec 31, 2024 | 1.35B | 232.63M | 20.82% |
| Dec 31, 2023 | 1.12B | -53.39M | -4.56% |
| Dec 31, 2022 | 1.17B | 147.58M | 14.43% |
| Dec 31, 2021 | 1.02B | 101.02M | 10.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.